Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Deudextromethorphan (Primary)
- Indications Agitation
- Focus Registrational; Therapeutic Use
- Sponsors Avanir Pharmaceuticals; Otsuka Pharmaceutical Development & Commercialization
- 12 Feb 2024 Primary endpoint (Change from Baseline to Week 12 in the composite Cohen-Mansfield) has not been met.
- 12 Feb 2024 Results published in an Otsuka Pharmaceutical Media Release.
- 09 Feb 2024 This trial has been completed in Czechia (End Date: 14 Dec 2023), according to European Clinical Trials Database record.